

21st December 2022

Dear Sir/ Madam,

**Subject: Updates on acquisition under Regulation 30
of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015**

The BSE Limited 1st floor, New Trading Ring Rotunda Building, P.J Towers Dalal Street, Mumbai - 400 001.	The National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, G. Block Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.
Script Code: 500259	Script Code: LYKALABS

Please refer to our earlier communication dated 9th November 2022, with reference to the proposed acquisition of animal healthcare business from Agilis Healthcare Private Limited.

Now we further wish to inform you that today the Company has finalised and signed the agreement with the Agilis Healthcare Private Limited as per the above referred disclosure.

Kindly take the note of the above information on your record.

Thanking You,

Yours faithfully,

For Lyka Labs Limited

Kunal N. Gandhi
Managing Director & CEO
DIN: 01516156